These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32683508)

  • 1. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding.
    Arai J; Goto K; Otoyama Y; Nakajima Y; Sugiura I; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Nozawa H; Nakagawa R; Muroyama R; Kato N; Yoshida H
    Cancer Immunol Immunother; 2021 Jan; 70(1):203-213. PubMed ID: 32683508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
    Arai J; Goto K; Stephanou A; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Morimoto S; Kaise Y; Lim LA; Yoshida H; Kato N
    J Gastroenterol Hepatol; 2018 May; 33(5):1075-1081. PubMed ID: 29055152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
    Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N
    Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Arai J; Goto K; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Kaise Y; Lim LA; Yoshida H; Kato N
    Int J Cancer; 2018 Nov; 143(10):2575-2583. PubMed ID: 29873070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10.
    Otoyama Y; Arai J; Goto K; Nozawa H; Nakagawa R; Muroyama R; Sugiura I; Nakajima Y; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Kato N; Yoshida H
    Anticancer Res; 2021 May; 41(5):2307-2320. PubMed ID: 33952456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.
    Ogawa K; Chiba T; Nakamura M; Arai J; Zhang J; Ma Y; Qiang NA; Ao J; Yumita S; Ishino T; Kan M; Iwanaga T; Nakagawa M; Fujiwara K; Sakuma T; Kanzaki H; Koroki K; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Kondo T; Nakagawa R; Ogasawara S; Muroyama R; Nakamoto S; Kanda T; Maruyama H; Kato J; Matsumoto S; Arai T; Motohashi S; Kato N
    Anticancer Res; 2023 Mar; 43(3):1043-1052. PubMed ID: 36854524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
    Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
    Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding.
    Fu R; Yu F; Wu W; Liu J; Li J; Guo F; Xu L; Wang F; Cui X
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108195. PubMed ID: 34678691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Tsunematsu H; Aono S; Shimizu S; Kodama T; Hikita H; Yamamoto M; Oze T; Aketa H; Hosui A; Miyagi T; Ishida H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    Cancer Immunol Immunother; 2012 Sep; 61(9):1425-32. PubMed ID: 22302133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
    Goto K; Annan DA; Morita T; Li W; Muroyama R; Matsubara Y; Ito S; Nakagawa R; Tanoue Y; Jinushi M; Kato N
    Sci Rep; 2016 Dec; 6():38407. PubMed ID: 27910927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
    Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
    Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.
    Fang L; Gong J; Wang Y; Liu R; Li Z; Wang Z; Zhang Y; Zhang C; Song C; Yang A; Ting JP; Jin B; Chen L
    J Exp Clin Cancer Res; 2014 Sep; 33(1):76. PubMed ID: 25228093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy.
    Oh S; Park Y; Lee HJ; Lee J; Lee SH; Baek YS; Chun SK; Lee SM; Kim M; Chon YE; Ha Y; Cho Y; Kim GJ; Hwang SG; Kwack K
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
    Yang H; Lan P; Hou Z; Guan Y; Zhang J; Xu W; Tian Z; Zhang C
    Br J Cancer; 2015 Jan; 112(1):112-21. PubMed ID: 25393367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
    Zhou C; Liu J; Li Y; Liu L; Zhang X; Ma CY; Hua SC; Yang M; Yuan Q
    FEBS Lett; 2011 Jun; 585(12):1828-34. PubMed ID: 21530512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.
    Takuma K; Fujihara S; Fujita K; Iwama H; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Shi T; Morishita A; Kobara H; Himoto T; Masaki T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
    Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
    Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.